Publications by authors named "Mike Baxter"

Claim this Profile
A
A Systematic Literature Review of Psychological Interventions for Adults with Type 1 Diabetes.
Onyinye Diribe, Karen Palmer, Adee Kennedy, Marissa Betts, Katarzyna Borkowska, Mike Baxter

Diabetes Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous Versus Sequential Initiation of Lixisenatide and Basal Insulin for Type 2 Diabetes: Subgroup Analysis of a Japanese Post-Marketing Surveillance Study of Lixisenatide (PRANDIAL).
Hideaki Kaneto, Mike Baxter, Yoko Takahashi, Yasuo Terauchi

Adv Ther· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Digital Solutions in Behavior Change Interventions for Type 2 Diabetes Mellitus: A Literature Review.
Cécile Baradez, Jan Liska, Claire Brulle-Wohlhueter, Divya Pushkarna, Mike Baxter

Diabetes Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP-O2 trial.
Katsumi Iizuka, Mike Baxter, Daisuke Watanabe, Daisuke Yabe

Diabetes Obes Metab· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK.
Rory J McCrimmon, Edel Falla, Jo Zhou Sha, Abdul Jabbar Omar Alsaleh, Elisheva Lew, Mike Baxter

Diabetes Ther· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post-hoc analysis of the LixiLan JP-L trial.
Daisuke Yabe, Katsumi Iizuka, Mike Baxter, Daisuke Watanabe, Hideaki Kaneto

J Diabetes Investig· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Real-World, Observational Study of the Initiation, Use, and Effectiveness of Basal-Bolus or Premixed Insulin in Japanese People with Type 2 Diabetes.
Hideaki Miyoshi, Mike Baxter, Takeshi Kimura, Masakatsu Hattori, Yukiko Morimoto

Diabetes Ther· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists in the treatment of Japanese people with type 2 diabetes: An innovative solution to a complex therapeutic challenge.
Hideaki Kaneto, Ryusuke Koshida, Mike Baxter

Diabetes Obes Metab· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials.
Yasuo Terauchi, Daisuke Yabe, Hideaki Kaneto, Atsushi Amano, Mike Baxter

Diabetes Obes Metab· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.
Mike Baxter, Yukiko Morimoto, Masami Tamiwa, Masakatsu Hattori, Xuejun Victor Peng

Diabetes Ther· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glycaemic variability: The under-recognized therapeutic target in type 1 diabetes care.
Emma G Wilmot, Pratik Choudhary, Lalantha Leelarathna, Mike Baxter

Diabetes Obes Metab· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial.
Melanie J Davies, David Russell-Jones, Thomas M Barber, Fernando J Lavalle-González, Gagik R Galstyan, Mike Baxter

Diabetes Obes Metab· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geriatrician input into nursing homes reduces emergency hospital admissions.
Radcliffe Lisk, Keefai Yeong, Ashraf Nasim, Mike Baxter, Bhaskar Mandal

Arch Gerontol Geriatr· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
Mike A Baxter

Acta Diabetol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of type 2 diabetes: a structured management plan.
Mike Baxter

Adv Ther· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis